Alector, Inc. reiterated earnings guidance for the year ending 2023. For the year, company continues to anticipate collaboration revenue to be between $90 and $100 million, total research and development to be between $210 million and $220 million and total general and administrative expenses to be between $60 million and $65 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.445 USD | -0.82% | +3.71% | -31.77% |
May. 14 | Transcript : Alector, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:55 AM | |
May. 08 | Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.77% | 529M | |
+8.90% | 114B | |
+11.47% | 104B | |
-12.65% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-3.02% | 17.89B | |
+8.37% | 14.28B | |
+35.08% | 12.55B |
- Stock Market
- Equities
- ALEC Stock
- News Alector, Inc.
- Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023